A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

NCT02296476 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class

Stopped This study was terminated due to lack of clinical activity and not due to safety reasons.

Conditions

Interventions

Sponsor

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)